Cipla has settled a trademark infringement case with German drug major Bayer Healthcare after it found Cipla's veterinary products were entering into the United States market, through Web site channels.
As per the settlement, Cipla will give up all profits it made from the sale of its DA Double Advantage, amounting in excess of $100,000, and discontinue all use of the trademark. It will also stop use of the trademark 'Advance' for a companion animal product and not make any product with the same formula as Bayer's Advantix, another patented flea preventative, during the remaining term of those patents.
Website operator Archipelago agreed to a consent decree, under which it is prohibited from selling DA Double Advantage and Advantix in the United States.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1464.85 |
Dr. Reddys Lab | 5955.65 |
Cipla | 1477.15 |
Zydus Lifesciences | 1050.35 |
Lupin | 1603.55 |
View more.. |